These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 23561587)
1. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study). Spadaccio C; Patti G; De Marco F; Coccia R; Di Domenico F; Pollari F; Zanzonico R; Pettinari M; Lusini M; Di Sciascio G; Covino E; Chello M Am J Cardiol; 2013 Jul; 112(1):21-6. PubMed ID: 23561587 [TBL] [Abstract][Full Text] [Related]
2. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting. Zhao K; Li YJ; Gao S Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458 [TBL] [Abstract][Full Text] [Related]
3. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341 [TBL] [Abstract][Full Text] [Related]
4. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention. Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511 [TBL] [Abstract][Full Text] [Related]
5. Preprocedural red blood cell distribution width predicts bare metal stent restenosis. Yildiz A; Tekiner F; Karakurt A; Sirin G; Duman D Coron Artery Dis; 2014 Sep; 25(6):469-73. PubMed ID: 24614629 [TBL] [Abstract][Full Text] [Related]
6. The value of peripheral blood eosinophil count in predicting in-stent restenosis in patients with stable angina pectoris undergoing drug eluting stenting. Hajizadeh R; Ghaffari S; Separham A; Shokouhi B; Kavandi H; Pourafkari L; Nader ND Rom J Intern Med; 2017 Dec; 55(4):229-236. PubMed ID: 28672766 [TBL] [Abstract][Full Text] [Related]
7. Late outcomes after drug-eluting stent implantation in "real-world" clinical practice. Ramsdale DR; Rao A; Asghar O; Ramsdale KA; McKay E J Invasive Cardiol; 2008 Oct; 20(10):493-500. PubMed ID: 18829991 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry. Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G; EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis. Yılmaz S; Sen F; Ünal S; Yayla C; Özeke Ö; Aras D; Topaloglu S; Aydogdu S Scand Cardiovasc J; 2015 Feb; 49(1):39-44. PubMed ID: 25414124 [TBL] [Abstract][Full Text] [Related]
10. Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents. Turak O; Canpolat U; Özcan F; Mendi MA; Oksüz F; Işleyen A; Gürel OM; Çay S; Aras D; Aydoğdu S Am J Cardiol; 2014 Jan; 113(2):197-202. PubMed ID: 24157191 [TBL] [Abstract][Full Text] [Related]
11. Impact of the first-generation drug-eluting stent implantation on periprocedural myocardial injury in patients with stable angina pectoris. Okada T; Yoshikawa D; Ishii H; Matsumoto M; Hayakawa S; Matsudaira K; Tanaka M; Kumagai S; Hayashi M; Ando H; Amano T; Murohara T J Cardiol; 2012 Oct; 60(4):264-9. PubMed ID: 22738692 [TBL] [Abstract][Full Text] [Related]
15. Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis. Lee CW; Park CB; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ Catheter Cardiovasc Interv; 2007 Jan; 69(1):104-8. PubMed ID: 17139669 [TBL] [Abstract][Full Text] [Related]
16. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients. Du R; Zhang RY; Zhu ZB; Zhang Q; Hu J; Yang ZK; Yan ZJ; Lv AK; Ding FH; Zhang JS; Shen WF Coron Artery Dis; 2010 May; 21(3):175-81. PubMed ID: 20305549 [TBL] [Abstract][Full Text] [Related]
17. Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry. Takagi K; Ielasi A; Shannon J; Latib A; Godino C; Davidavicius G; Mussardo M; Ferrarello S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A Circ Cardiovasc Interv; 2012 Aug; 5(4):491-8. PubMed ID: 22851528 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of patients and types of lesions in patients with drug-eluting or bare-metal stent implantation in small coronary arteries: from the FU-Registry. Sugihara M; Miura S; Nishikawa H; Ike A; Mori K; Iwata A; Kawamura A; Saku K J Cardiol; 2013 Feb; 61(2):117-21. PubMed ID: 23159206 [TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Park DW; Lee CW; Yun SC; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ Heart; 2007 Sep; 93(9):1087-92. PubMed ID: 17309906 [TBL] [Abstract][Full Text] [Related]
20. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Türker S; Güneri S; Akdeniz B; Ozcan MA; Baris N; Badak O; Kirimli O; Yüksel F Am J Cardiol; 2006 Jan; 97(2):198-202. PubMed ID: 16442363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]